Chemoprevention of radiation-induced mammary tumors in rats by bezafibrate administered together with diethylstilbestrol as a promoter.
Pregnant Wistar-MS strain rats were irradiated with 2.6 Gy of gamma-rays at day 20 of pregnancy. Rats in the control group (n = 48) were then implanted with a diethylstilbestrol (DES) pellet at 35 days after weaning, while being fed a control (MB-1) diet. The incidence of mammary tumors was 89.6% within 1 year. In the experimental group (n = 22), a bezafibrate (0.15%) diet was initiated immediately after weaning, and 35 days after weaning a DES pellet was implanted. Administration of dietary bezafibrate together with DES-implantation continued for a period of 1 year, at which time the experiment was terminated. The incidence (27.3%) of the mammary tumors in the bezafibrate-fed rats was less than one-third of that in the control rats. Compared with the control group, the number of mammary tumors per tumor-bearing rat in the bezafibrate-treated group was reduced. For clarification of the mechanism of the chemopreventive effects of bezafibrate, lipid and hormone concentrations in serum were measured. Bezafibrate-fed rats showed a significant decrease in serum prolactin (56%) and triglyceride (63%) concentrations, and a significant increase in serum estradiol-17beta (3.8-fold), cholesterol ester (2.0-fold) and TSH (2.0-fold) concentrations in comparison with the control rats. The bezafibrate diet inhibited the formation of DES-induced pituitary tumors. However, the development of mammary glands in the bezafibrate-fed rats was stimulated more than that in the control rats treated with DES alone. The present results demonstrate that bezafibrate is effective in preventing mammary tumors induced by radiation together with DES, possibly by reducing prolactin and triglyceride concentrations.
Inano
H
H
The First Research Group, National Institute of Radiological Sciences, Inage-ku, Japan.
Suzuki
K
K
Wakabayashi
K
K
D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001629:Bezafibrate / Q000627:therapeutic use*; D002273:Carcinogens / Q000633:toxicity*; D004054:Diethylstilbestrol / Q000633:toxicity*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000097:blood; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008325:Mammary Neoplasms, Experimental / Q000517:prevention & control*; D009381:Neoplasms, Radiation-Induced / Q000517:prevention & control*; D011247:Pregnancy; D011388:Prolactin / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D012739:Gonadal Steroid Hormones; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D004054:Diethylstilbestrol; D011388:Prolactin; D001629:Bezafibrate